Survivin、Ki-67在食管鳞癌中的表达及意义
|
摘要
食管癌近年来发病率虽然有所降低,但是因为缺乏有效的早期发现、诊断方法,发现时大都已处于中晚期,治疗效果不佳。寻找一种或者多种特异性较高的肿瘤生物学标志物是大家共同的期待。
抗凋亡蛋白survivin在细胞凋亡和细胞分裂中发挥着双重作用,近年来的研究发现,该蛋白与食管鳞癌组织的分化和肿瘤细胞的浸润有较大关系,可能是与survivin的高表达抑制了细胞凋亡、促进肿瘤细胞的蔓延有关。本研究通过免疫组织化学方法探讨survivin在食管癌组织和癌周组织中的表达与分化状态、浸润深度等临床病理特征的关系,检测了体外培养的食管鳞癌细胞中survivin表达并分析了其与细胞分化的相关性,提示survivin蛋白可能为食管癌分化和浸润过程中较为特异的标志物。Ki-67是一种较明确的细胞增值抗原。
1.采用免疫组化SP法分别对40例食管鳞癌组织中及20例癌旁组织中Survivin、Ki-67的表达情况进行检测。
2.用免疫细胞化学方法分别检测人食管上皮永生细胞系及不同分化程度的鳞状上皮肿瘤细胞系中Survivin的表达情况。
3.采用SPSS13.0统计软件,根据资料类型,统计方法采用X2检验及Continuity Correction连续矫正检验和直线相关回归分析。P<0.05为有统计学差异。
1.Survivin、Ki-67在食管鳞癌组织和癌旁组织中表达情况
肿瘤组织中survivin、ki-67两种蛋白的阳性表达和癌周正常组织明显不同,有统计学意义(P<0.05)。
2. Survivin、Ki-67在食管鳞癌组织中的表达与临床病理关系Survivin蛋白在浸润之浅层、深层肿瘤组织阳性率明显不同,组间阳性率差异明显,在统计学上有意义(P<0.05)；不同分化状态肿瘤组织阳性率组间差异有统计学意义(P<0.05),其表达高低与临床其它病理特征没有明显的关系。Ki67蛋白在浸润之浅层、深层肿瘤组织阳性表达明显不同,组间阳性率差异有统计学意义(P<0.05)；不同分化状态肿瘤组织中阳性率组间差异明显,统计学上有意义(P<0.05),其表达高低与临床其它病理特征无相关性。
3.食管鳞癌组织中Survivin和Ki-67蛋白表达的相互关系Spearman等级相关方法检验分析显示,Survivin和Ki-67蛋白在食管鳞癌组织中的表达呈正相关(P<0.05)。
4. KRSE-70细胞系survivin蛋白阳性表达率为85%,KYSE-450细胞系表达率为53.8%,Het-1A细胞系表达率为5.3%。3系不同分化状态的细胞survivin阳性表达率有明显的不同,统计学上有意义(P<0.01)。
1. Survivin在食管鳞癌组织及体外培养的鳞癌细胞中的表达明显高于正常组织,且与患者年龄、性别、淋巴结转移等无关,与肿瘤组织浸润深度、分化程度有明显关系。
2.Ki-67在食管鳞癌组织中的表达明显高于正常组织,且与患者年龄、性别、淋巴结转移无关,与肿瘤组织浸润深度、分化程度有明显关系。
3. survivin与ki-67在食管鳞癌组织中的表达一致,具有明显的相关性。
4.联合检测食管鳞癌中survivin和ki67蛋白的表达,可以提示食管癌的发生及分化程度,为治疗方法的选择提供一定理论依据。
Esophageal cancer is a common gastrointestinal tumor. Its low early diagnosis rate has led to a large proportion of esophageal cancer detected in mid and late stage, resulting in poor treatment outcome. Thus, the key to its treatment is early detection, which requires highly specific biological marker.
Anti-apoptotic protein survivin plays a dual role in apoptosis and cell division. Recent studies have found close relation between survivin and differentiation of esophageal squamous cell carcinoma as well as infiltration of tumor cells. A high survivin expression is also proposed in suppressed apoptosis and in metastasis. Using immunohistochemical methods, the present study demonstrated the relation of cellular differentiation status and invasion depth to survivin expression in esophageal squamous cell carcinoma. It was also hoped that the results of this study would strengthen current body of evidence for specific biological marker in detection of early esophageal cancer and esophageal cancer differentiation. Ki-67 is a more specific cell proliferation antigen.
1. The levels of expression of surviving and Ki-67 were detected using immunohistochemical SP from 40 samples of esophageal squamous cell carcinoma and 20 samples of adjacent tissues.
2. Using immune chemical methods, the levels of expression of surviving in normal esophageal epithelial cells (Het-IA), well-differentiated esophageal squamous epithelial cells (KYSE-70) and poorly differentiated squamous cell epithelial cells (KYSE-450).
3. Statistical analysis, continuity correction and X2 test, were performed using SPSS 13.0. (P≤0.05 was designated to be statistically significant).
1. Expression of survivin, ki-67 in esophageal squamous cell carcinoma and adjacent tissues
Esophageal cancer survivin, ki-67 gene expression was significantly different from the adjacent tissue (P<0.05).
2. Survivin, Ki-67 in esophageal squamous cell carcinoma and the clinical pathology Statistically significantly difference in Survivin and Ki-67 expressions were found in tumours of different invasion depth and different differential status (p<0.05).Levels of Survivin and Ki-67 expressions were not found to be influenced by other pathological characteristics.
3. Expression of Survivin and Ki-67 in esophageal squamous cell carcinoma Spearman rank correlation method of test analysis showed a positive correlation between the expression of Survivin and Ki-67 protein in esophageal squamous cell carcinoma (P<0.05).
4. Survivin expression in KRSE-70 cells, KYSE-450 cells and Het-IA cells were 85%,53.8% and 5.3% respectively. Statistically significant difference in the levels of Survivin expression were found in abovementioned cell lines of different differentiatial status (P<0.01).
The expression of Survivin and Ki-67 in squamous cell carcinoma was significantly higher than that in normal tissue. The levels of expression were found to have positive correlation with the status of differentiation and invasion, while age, gender and lymph node appeared to have minimal relation to the expression.
抗凋亡蛋白survivin在细胞凋亡和细胞分裂中发挥着双重作用,近年来的研究发现,该蛋白与食管鳞癌组织的分化和肿瘤细胞的浸润有较大关系,可能是与survivin的高表达抑制了细胞凋亡、促进肿瘤细胞的蔓延有关。本研究通过免疫组织化学方法探讨survivin在食管癌组织和癌周组织中的表达与分化状态、浸润深度等临床病理特征的关系,检测了体外培养的食管鳞癌细胞中survivin表达并分析了其与细胞分化的相关性,提示survivin蛋白可能为食管癌分化和浸润过程中较为特异的标志物。Ki-67是一种较明确的细胞增值抗原。
1.采用免疫组化SP法分别对40例食管鳞癌组织中及20例癌旁组织中Survivin、Ki-67的表达情况进行检测。
2.用免疫细胞化学方法分别检测人食管上皮永生细胞系及不同分化程度的鳞状上皮肿瘤细胞系中Survivin的表达情况。
3.采用SPSS13.0统计软件,根据资料类型,统计方法采用X2检验及Continuity Correction连续矫正检验和直线相关回归分析。P<0.05为有统计学差异。
1.Survivin、Ki-67在食管鳞癌组织和癌旁组织中表达情况
肿瘤组织中survivin、ki-67两种蛋白的阳性表达和癌周正常组织明显不同,有统计学意义(P<0.05)。
2. Survivin、Ki-67在食管鳞癌组织中的表达与临床病理关系Survivin蛋白在浸润之浅层、深层肿瘤组织阳性率明显不同,组间阳性率差异明显,在统计学上有意义(P<0.05)；不同分化状态肿瘤组织阳性率组间差异有统计学意义(P<0.05),其表达高低与临床其它病理特征没有明显的关系。Ki67蛋白在浸润之浅层、深层肿瘤组织阳性表达明显不同,组间阳性率差异有统计学意义(P<0.05)；不同分化状态肿瘤组织中阳性率组间差异明显,统计学上有意义(P<0.05),其表达高低与临床其它病理特征无相关性。
3.食管鳞癌组织中Survivin和Ki-67蛋白表达的相互关系Spearman等级相关方法检验分析显示,Survivin和Ki-67蛋白在食管鳞癌组织中的表达呈正相关(P<0.05)。
4. KRSE-70细胞系survivin蛋白阳性表达率为85%,KYSE-450细胞系表达率为53.8%,Het-1A细胞系表达率为5.3%。3系不同分化状态的细胞survivin阳性表达率有明显的不同,统计学上有意义(P<0.01)。
1. Survivin在食管鳞癌组织及体外培养的鳞癌细胞中的表达明显高于正常组织,且与患者年龄、性别、淋巴结转移等无关,与肿瘤组织浸润深度、分化程度有明显关系。
2.Ki-67在食管鳞癌组织中的表达明显高于正常组织,且与患者年龄、性别、淋巴结转移无关,与肿瘤组织浸润深度、分化程度有明显关系。
3. survivin与ki-67在食管鳞癌组织中的表达一致,具有明显的相关性。
4.联合检测食管鳞癌中survivin和ki67蛋白的表达,可以提示食管癌的发生及分化程度,为治疗方法的选择提供一定理论依据。
Esophageal cancer is a common gastrointestinal tumor. Its low early diagnosis rate has led to a large proportion of esophageal cancer detected in mid and late stage, resulting in poor treatment outcome. Thus, the key to its treatment is early detection, which requires highly specific biological marker.
Anti-apoptotic protein survivin plays a dual role in apoptosis and cell division. Recent studies have found close relation between survivin and differentiation of esophageal squamous cell carcinoma as well as infiltration of tumor cells. A high survivin expression is also proposed in suppressed apoptosis and in metastasis. Using immunohistochemical methods, the present study demonstrated the relation of cellular differentiation status and invasion depth to survivin expression in esophageal squamous cell carcinoma. It was also hoped that the results of this study would strengthen current body of evidence for specific biological marker in detection of early esophageal cancer and esophageal cancer differentiation. Ki-67 is a more specific cell proliferation antigen.
1. The levels of expression of surviving and Ki-67 were detected using immunohistochemical SP from 40 samples of esophageal squamous cell carcinoma and 20 samples of adjacent tissues.
2. Using immune chemical methods, the levels of expression of surviving in normal esophageal epithelial cells (Het-IA), well-differentiated esophageal squamous epithelial cells (KYSE-70) and poorly differentiated squamous cell epithelial cells (KYSE-450).
3. Statistical analysis, continuity correction and X2 test, were performed using SPSS 13.0. (P≤0.05 was designated to be statistically significant).
1. Expression of survivin, ki-67 in esophageal squamous cell carcinoma and adjacent tissues
Esophageal cancer survivin, ki-67 gene expression was significantly different from the adjacent tissue (P<0.05).
2. Survivin, Ki-67 in esophageal squamous cell carcinoma and the clinical pathology Statistically significantly difference in Survivin and Ki-67 expressions were found in tumours of different invasion depth and different differential status (p<0.05).Levels of Survivin and Ki-67 expressions were not found to be influenced by other pathological characteristics.
3. Expression of Survivin and Ki-67 in esophageal squamous cell carcinoma Spearman rank correlation method of test analysis showed a positive correlation between the expression of Survivin and Ki-67 protein in esophageal squamous cell carcinoma (P<0.05).
4. Survivin expression in KRSE-70 cells, KYSE-450 cells and Het-IA cells were 85%,53.8% and 5.3% respectively. Statistically significant difference in the levels of Survivin expression were found in abovementioned cell lines of different differentiatial status (P<0.01).
The expression of Survivin and Ki-67 in squamous cell carcinoma was significantly higher than that in normal tissue. The levels of expression were found to have positive correlation with the status of differentiation and invasion, while age, gender and lymph node appeared to have minimal relation to the expression.
引文
[1]王立东,郑树.河南食管癌高发区人群食管和贲门癌变机制[J].郑州大学学报(医学版),2002,37(6)：717-729
[2]AmbrosiniG,Adida C,Altieri DC:A novel anti-apoptosis gene,survivin,expressed in cancer and lymphoma.Nat Med 3:917-921,1997.
[3]Adida C,Crotty PL,McGrath J,Berrebi D,Diebold J,Altieri DC:Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation.Am J Pathol 152:43-49,1998.
[4]Grabowski P,Kuhnel T,Muhr-Wilkenshoff F,Heine B,Stein H,Hopfner M,Germer CT, Scherubl H:Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma.Br J Cancer 88:115-119,2003.
[5]Kato J,Kuwabara Y,Mitani M,Shinoda N,Sato A,Toyama T,Mitsui A,Nishiwaki T, Moriyama S,Kudo J et al:Expression of survivin in esophageal cancer:correlation with the prognosis and response to chemotherapy.Int J Cancer 95:92-95,2001.
[6]Ikeguchi M,Yamaguchi K,Kaibara N:Survivin gene expression positively correlates with proliferative activity of cancer cells in esophageal cancer.Tumour Biol 24:40-45,2003.
[7]Choi N,Baumann M,Flentjie M,Kellokumpu-Lehtinen P,Senan S,Zamboglou N, Kosmidis P:Predictive factors in radiotherapy for non-small cell lung cancer:present status.Lung Cancer 31:43-56,2001.
[8]Gianani R,Jarboe E,Orlicky D,Frost M,Bobak J,Lehner R,Shroyer KR:Expression of survivin in normal,hyperplastic,and neoplastic colonic mucosa.Hum Pathol 32:119-125,2001.
[9]Nassar A,Lawson D,Cotsonis G,Cohen C:Survivin and Caspase-3 Expression in Breast Cancer:Correlation With Prognostic Parameters,Proliferation,Angiogenesis, and Outcome.Appl Immunohistochem Mol Morphol,2008.
[10]潘艳东,黎静,李志强等.Ki67,VEGF和EGFR的表达与鼻咽癌临床分期及分化程度的关系[J]广东医学,2009;30(7)：1095-1097
[11]杨映红,林明稀,郑宇辉等.分化抑制蛋白IdⅠ和PCNA及Ki67在肝细胞癌中的表达及意义[J]中国肿瘤临床与康复,2008；15(1)：30-32
[12]蒋立艳,王自能.恶性上皮源性卵巢肿瘤多向分化与Ki67蛋白表达的相关性[J]暨南大学学报·自然科学与医学版,2006；(2)：257-261
[13]汲振余,赵立群,杨观瑞等.食管鳞癌细胞分化状态对内源性光敏剂PpIX产量的影响及对PDT的应答[J].世界华人消化杂志,2006,14(01)：6-11
[14]Zangemeister-WittkeU,SimonHU.An IAP in action the multiple roles of survivin in differentiation,immunity and malignance [J].Cell Cycle,2004,3(9):1121-1123
[15]Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003;22:8581-8589.
[16]Schmit t CA. Senescence,apoptosis and therapy—cutting the lifelines of cancer [J]. Nat Rev Cancer,2003,3 (4):2862295
[17]Shibata H,Mat subara O. Apoptosis as an independent prog2 nostic indicator in squamous cell carcinoma of the esophagus [J]. Pathol Int,2001,51 (7):498-503
[18]Altieri DC. Survivin,versatile modulation of cell division and apoptosis in cancer [J] Oncogene,2003,22 (53):8581-8589
[19]Ikeguchi M,Yamaguchi K,Kaibara N. Survivin gene expres2 sion positively correlates with proliferative activity of cancer cells in esophageal cancer [J]. Tumour Biol,2003,24 (1):402-405
[20]Grabowski P, Kii hnel T,Mii hr2Wilkenshoff F, et al. Prog2 nostic value of nuclear survivin expression in oesophageal squamous cell carcinoma[J]. Br J Cancer,2003,88 (1):115-119
[21]Nemoto T, Kitagawa M, Hasegawa M,et al. Expression of IAP family proteins in esophageal cancer [J]. Exp Mol Pathol,2004,76 (3):253-259
[22]9.Vagnarelli,P. et al. (2004) Chromosomal passengers:the four-dimensional regulation of mitotic events. Chromosoma,113,211-222
[23]Li,F. et al. (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature, 396,580-584.
[24]Li,F. et al. (1999) The cancer antiapoptosis mouse survivin gene:characterization of locus and transcriptional requirements of basal and cell cycledependent expression. Cancer Res.,59, 3143-3151.
[25]Kim,P.J. et al. (2003) Survivin and molecular pathogenesis of colorectal cancer. Lancet,362, 205-209.
[26]Gritsko,T. et al. (2006) Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res. 12,11-19.
[27]Song,J. et al. (2005) Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion. Immunity,22,621-631.
[28]Mitsiades,C.S. et al. (2002) Activation of NF-kB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene,21,5673-5683.
[29]Vogelstein,B. et al. (2004) Cancer genes and the pathways they control. Nat. Med.,10, 789-799.
[30. Xia,F. et al. (2006) Mitosis-independent survivin gene expression in vivo and regulation by p53. Cancer Res.,66,3392-3395.
[31]Marusawa,H. et al. (2003) HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J.,22,2729-2740.
[32]Dohi,T. et al. (2004) An IAP-IAP complex inhibits apoptosis. J. Biol. Chem.,279,34087-34090.
[33]. Dohi,T. et al. (2004) Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J.Clin. Invest.,114,1117-1127.
[34]O, Connor DS, Schechner S,Adida C,etal.Control of apoptosis during angiogenesis by survivin expression in endothelial cells[J].AmJ Pathol,2000,156(2):393-398.
[35]J. Taran, Z. Master, J.I. Yu, J. Rak, D.J. Dumont, R.S. Kerbel, A role of survivin in chemoresistance of endothelial cells mediated by VEGF, Proc. Natl Acad. Sci. USA 99 (2002) 4345-4349.
[36]X. Ling, F. Li, Silencing of anti-apoptotic survivin gene by multiple approaches of RNA interference technology, Biotech-niques 36 (2004) 450-454.
[37]N.K. Sah, A. Munshi, T. Mukhopadhyay, R.E. Meyn, Down regulation of the survivin gene shares HDAC and PI3K pathways and enhances radiosensitization of the human epidermoid carcinoma A431 cells, (submitted for publication).
[38]K.S. Choi, T.H. Lee, M.H. Jung, Ribozyme mediated cleavage of the human survivin mRNA and inhibition of anti-apoptotic function of survivin in MCF-7 cells, Cancer Gene Ther. 10 (2003) 87-95.
[39]M. Pennati, M. Binda, G Colella, M. Folini, L. Citti, R. Villa, et al., Radiosensitization of melanoma cells by ribozyme mediated inhibition of survivin expression, J. Invest. Dermatol.120 (2003) 648-654.
[40]F. Li, H. Huang, L. Brattain, P. Apontes, J. Wu, L. Binderup, M.G. Brattain, Differential expression of survivin and apoptosis by vitamin D3in two isogenic MCF-7 breast cancer cell sublines. Oncogene24 (2005) 1385-1395.
[41]Endl E, Gerdes J. The Ki-67 protein:fascinating forms and an unknown function. Exp. Cell Res.2000; 257; 231-237.
[42]Schluter C, Duchrow M, Wohlenberg C et al. The cell proliferation-associated antigen of antibody Ki-67:a very large,ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J. Cell Biol.1993; 123; 513-522.
[43]Hofmann K, Bucher P. The FHA domain:a putative nuclear signalling domain found in protein kinases and transcription factors. Trends Biochem. Sci.1995; 20; 347-349.
[44]Verheijen R, Kuijpers HJ, Schlingemann RO et al. Ki-67 detects a nuclear matrix-associated proliferation-related antigen. I. Intracellular localization during interphase. J. Cell Sci.1989; 92; 123-130.
[45]19. Rose DS, Maddox PH, Brown DC. Which proliferation markers for routine immunohistology? A comparison of (?)ve antibodies. J. Clin. Pathol.1994; 47; 1010-1014.
[46]Brown DC, Gatter KC. Monoclonal antibody Ki-67:its use in histopathology. Histopathology 1990; 17; 489-503.
[1]Ambosini G, Adida C, Altieti DC, etal.A novel anti-apoptosis gene,survivin,expressed in canser and lymphoma[J]. Nat Med,1997,3(8):917-921.
[2]Chantalatl,Skoufiasda,Klemanjp,et al.Crystal structure of human survivin reveals a bowtie-shaped dimer with two unusual alpha-helical extensions [J]. MolCell,2000, 6(1):183-189.
[3]Ambrosini G,Adidac ALTieri DC.A novel anti-apoptosis gene,survivin,expressed in cancer and Lymphoma[J].NatMed,1997,3(8):917'921.
[4]Sirieix PS,O'Donovan M,Brown J,et al.Surface expression of minichromosome maintenance proteins provides a novel method for detecting patients at risk for developing adenocarcinoma in Barrett's esophagus.Clin Cancer Res,2003,Vol.9(7):2560-2566
[5]Ambrosini QAdida C,Atieri DC.A novel anti-apoptosis gene,Survivin,expressed in cancer and lymphoma.Nat Med,1997,Vol.3(8):917-921
[6]Holley CL, Olson MR, Colon-Ramos DA, Kornbluth S:Reaper eliminates IAP proteins through stimulated IAP degradation and generalized translational inhibition. Nat Cell Biol 2002,4:439-444.
[7]Salvesen GS, Duckett CS:Apoptosis:IAP proteins:blocking the road to death's door. Nat Rev Mol Cell Biol 2002,3:401-410.
[8]Fraser AG, James C, Evan GI, Hengartner MO:Caenorhabditis elegans inhibitor of apoptosis protein (IAP) homologue BIR-1 plays a conserved role in cytokinesis. Curr Biol 1999, 9:292-301.
[9]Verdecia MA, Huang H, Dutil E, Kaiser DA, Hunter T, Noel JP:Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol 2000, 7:602-608.
[10]Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, Chung CW, Jung YK, Oh BH:An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and-7. Biochemistry 2001,40:1117-1123.
[11]Altieri DC:Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003,3:46-54.
[12]Zangemeister-Wittke U, Simon HU:An IAP in action:themultiple roles of survivin in differentiation, immunity and malignancy. Cell Cycle 2004,3:1121-1123.
[13]Wheatley SP, McNeish IA:Survivin:a protein with dual roles in mitosis and apoptosis. Int Rev Cytol 2005,247:35-88.
[14]Grossman D, Kim PJ, Blanc-Brude OP, Brash DE, Tognin S, Marchisio PC, Altieri DC: Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J Clin Invest 2001,108:991-999.
[15]Dohi T, Salz W, Costa M, Ariyan C, Basadonna GP, Altieri DC:Inhibition of apoptosis by survivin improves transplantation of pancreatic islets for treatment of diabetes in mice. EMBO Rep 2006,7:438-443.
[16]Okada H, Bakal C, Shahinian A, Elia A, Wakeham A, Suh WK,Duncan GS, Ciofani M, Rottapel R, Zuniga-Pflucker JC et al.:Survivin loss in thymocytes triggers p53-mediated growth arrest and p53-independent cell death. J Exp Med 2004,199:399-410.
[17]Jones G, Jones D, Zhou L, Steller H, Chu Y:Deterin, a new inhibitor of apoptosis from Drosophila melanogaster. J Biol Chem 2000,275:22157-22165.
[18]Walter D, Wissing S, Madeo F, Fahrenkrog B:The inhibitor-of-apoptosis protein Birlp protects against apoptosis in S. cerevisiae and is a substrate for the yeast homologue of Omi/HtrA2. J Cell Sci 2006,119:1843-1851.
[19]Huang HK, Bailis JM, Leverson JD, Gomez EB, Forsburg SL,Hunter T:Suppressors of Birlp (survivin) identify roles for the chromosomal passenger protein Piclp (INCENP) and the replication initiation factor Psf2p in chromosome segregation. Mol Cell Biol 2005, 25:9000-9015.
[20]Salvesen GS, Duckett CS:Apoptosis:IAP proteins:blocking the road to death's door. Nat Rev Mol Cell Biol 2002,3:401-410.
[21]Eckelman BP, Salvesen GS:The human anti-apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspases. J Biol Chem 2006,281:3254-3260.
[22]Vucic D, Franklin MC,Wallweber HJ, Das K, Eckelman BP, Shin H, Elliott LO, Kadkhodayan S, Deshayes K, Salvesen GS et al.:Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor:implications for Smac-dependent anti-apoptotic activity of ML-IAP. Biochem J 2005,385:11-20.
[23]Shin H, Renatus M, Eckelman BP, Nunes VA, Sampaio CA,Salvesen GS:The BIR domain of IAP-like protein 2 is conformationally unstable:implications for caspase inhibition. Biochem J 2005,385:1-10.
[24]Davoodi J, Lin L, Kelly J, Liston P, MacKenzie AE:Neuronal apoptosis-inhibitory protein does not interact with Smac and requires ATP to bind caspase-9. J Biol Chem 2004, 279:40622-40628.
[25]Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC:The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 1997,16:6914-6925.
[26]. Hao Y, Sekine K, Kawabata A, Nakamura H, Ishioka T, Ohata H, Katayama R, Hashimoto C, Zhang X, Noda T et al.:Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function. Nat Cell Biol 2004,6:849-860.
[27]Marusawa H, Matsuzawa S, Welsh K, Zou H, Armstrong R, Tamm I, Reed JC:HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J 2003,22:2729-2740.
[28]Dohi T, Okada K, Xia F, Wilford CE, Samuel T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S et al.:An IAP-IAP complex inhibits apoptosis. J Biol Chem 2004, 279:34087-34090.
[29]Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC:Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004,114:1117-1127.
[30]Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G:Cell death by mitotic catastrophe:a molecular definition. Oncogene 2004,23:2825-2837.
[31]Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003;22:8581-8589.
[32]. Grossman, D. et al. (1999) Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J. Invest. Dennatol.113,1076-1081
[33]Plantaz, D. et al. (1997) Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am. J. Pathol.150,81-89
[34]18 Islam, A. et al. (2000) High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19,617-623
[35]Hattori, M. et al. (2001) DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes. Cancer Lett.169,155-164
[36]Ambrosini,G. et al. (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med.,3,917-921.
[37]Fukuda,S. et al. (2006) Survivin, a cancer target with an emerging role in normal adult tissues. Mol. Cancer Ther.,5,1087-1098.
[38]. Mesri,M. et al. (2001) Suppression of vascular endothelial growth factormediated endothelial cell protection by survivin targeting. Am. J. Pathol.,158,1757-1765.
[39]Altznauer,F. et al. (2004) Inflammation-associated cell cycle-independent block of apoptosis by survivin in terminally differentiated neutrophils. J. Exp. Med.,199,1343-1354.
[40]Xing,Z. et al. (2004) Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J. Exp. Med.,199,69-80.
[41]Gurbuxani,S. et al. (2005) Differential requirements for survivin in hematopoietic cell development. Proc. Natl Acad. Sci. USA,102,11480-11485.
[42]Fukuda,S. et al. (2001) Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(t) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood,98,2091-2100. H.Deguchi,M. et al. (2002) Expression of survivin during liver regeneration. Biochem. Biophys. Res. Commun.,297,59-64.
[43]Chiou,S.K. et al. (2003) Survivin expression in the stomach:implications for mucosal integrity and protection. Biochem. Biophys. Res. Commun.,305,374-379.
[44]Wang,Y. et al. (2004) Survivin expression in rat testis is up-regulated by stem-cell factor. Mol. Cell Endocrinol.,218,165-174.
[45]Altieri,D.C. (2003) Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene,22,8581-8589.
[46]Florrel,S.R. et al. (2005) Proliferation, apoptosis, and survivin expression in a spectrum of melanocytic nevi. J. Cutan. Pathol.,32,45-49.
[47]Vetter,C.S. et al. (2005) Cytoplasmic and nuclear expression of survivin in melanocytic skin lesions. Arch. Dermatol. Res.,297,26-30.
[48]Velculescu,V.E. et al. (1999) Analysis of human transcriptomes. Nat. Gen.,23,387-388.
[49]Gritsko,T. et al. (2006) Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res.,12,11-19.
[50]Jiang,Y. et al. (2004) Aberrant regulation of survivin by the RB/E2F family of proteins. J. Biol. Chem.,279,40511-40520.
[51]Sommer,K.W. et al. (2003) Inhibitor of apoptosis protein (IAP) survivin is up-regulated by oncogenic c-H-Ras. Oncogene,22,4266-4280.
[52]Fukuda,S. et al. (2004) Activated H-Ras regulates hematopoietic cell survival by modulating survivin. Biochem. Biophys. Res. Commun.,323,636-644.
[53]Hoffman,W.H. et al. (2002) Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem.,277,3247-3257.
[54]Zhang,T. et al. (2001) Evidence that APC regulates survivin expression:a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res.,61,8664-8667.
[55]Fengzhi,L. et al. (2005) Nuclear or cytoplasmic expression of survivin:what is the significance? Int. J. Cancer,114,509-512.
[56]Islam,A. et al. (2000) Role of survivin, whose gene is mapped to 17q25, in human neuroblastoma and identification of a novel dominant-negative isoform, survivin-b/2B. Med. Pediatr. Oncol.,35,550-553.
[57]Monzo, M. et al. (1999) A novel anti-apoptosis gene:Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J. Clin. Oncol.17,2100-2104
[58]Tanaka, K. et al. (2000) Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin. Cancer Res.6,127-134
[59]Kawasaki, H. et al. (1998) Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res.58,5071-5074
[60]Kato, J. et al. (2001) Expression of survivin in esophageal cancer:Correlation with the prognosis and response to chemotherapy. Int. J. Cancer 95,92-95
[61]Yoshida, H. et al. (2001) Survivin, Bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell-and serous-type ovarian carcinomas. Int. J. Oncol.19,537-542
[62]Adida, C. et al. (2000) Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 96,1921-1925
[63]Sarela, A.I. et al. (2001) Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. Ann. Surg. Oncol.8,305-310
[64]Islam, A. et al. (2000) High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19,617-623
[65]Adida, C. et al. (2000) Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br. J. Haematol. 111,196-203
[66]Adida, C. et al. (1998) Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 351,882-883
[67]Swana, H.S. et al. (1999) Tumor content'of the anti-apoptosis molecule survivin and recurrence of bladder cancer. New Engl. J. Med.341,452-453
[68]Satoh, K. et al. (2001) Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 92,271-278
[69]. Schmitz, M. et al. (2000) Generation of survivin-specific CD8+T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res.60,4845-4849
[70]Andersen, M.H. et al. (2001) Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res.61,869-872
[71]Smith, S.D. et al. (2001) Urine detection of survivin and diagnosis of bladder cancer. J. Am. Med. Assoc.285,324-328
[72]O'Connor, D.S. et al. (2000) Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc. Natl. Acad. Sci. U. S. A.97,13103-13107
[73]Grossman,D. et al. (1999) Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J. Invest. Dermatol.,113,1076-1081.
[74]Cao,C. et al. (2004) XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene,23,7047-7052.
[75]Sharma,H. et al. (2005) Antisense-mediated downregulation of antiapoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy. Cancer Biol. Ther.,4,720-727.
[76]Fuessel,S. et al. (2004) Systematic in vitro evaluation of survivin directed antisense oligodeoxynucleotides in bladder cancer cells. J. Urol.,171,2471-2476.
[77]Ansell,S.M. et al. (2004) Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia,18,616-623.
[79]Sah,N.K. et al. (2006) Effect of downregulation of survivin expression on radiosensitivity of human epidermoid carcinoma cells. Int. J. Radiat. Oncol. Biol. Phys.,66,852-859. M.Pennati et al.1138
[80]Kanwar,J.R. et al. (2001) Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J. Natl Cancer Inst.,93,1541-1552.
[81]Izquierdo,M. (2005) Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther.,12,217-227.
[82]Carvalho,A. et al. (2003) Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J. Cell Sci.,116,2987-2998.
[83]Yang,D. et al. (2004) Cell division and cell survival in the absence of surviving. Proc. Natl Acad. Sci. USA,101,15100-15105.
[84]Ai,Z. et al. (2006) Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer. Cancer,107,746-756.
[85]Paduano,F. et al. (2006) Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygelda-namycin in human prostate cancer cells. Mol. Cancer Ther.,5,179-186.
[86]Nakao,K. et al. (2006) Survivin downregulation by siRNA sensitizes human hepatoma cells to TRAIL-induced apoptosis. Oncol. Rep.,16,389-392.
[87]Lens,S.M. et al. (2003) Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J.,22,2934-2947.
[88]Beltrami,E. et al. (2004) Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis. J. Biol. Chem.,279, 2077-2084.
[89]Jiang,G. et al. (2006) Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma. Cancer Biol. Ther.,5,435-440.
[90]93. Jiang,G. et al. (2006) Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma. Cancer Biol. Ther.,5,435-440.
[91]Li,Q.X. et al. (2006) Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers. Cancer Biol. Ther.,5,860-866.
[92]Yonesaka,K. et al. (2006) Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin. Int. J. Cancer,118,812-820.
[93]Kappler,M. et al. (2005) Radiosensitization after a combined treatment of survivin siRNA and irradiation, is correlated with the activation of caspases 3 and 7 in a wt-p53 sarcoma cell line, but not in a mt-p53 sarcoma cell line. Oncol. Rep.,13,167-172.
[94]Coma,S. et al. (2004) Use of siRNAs and antisense oligonucleotides against survivin RNA to inhibit steps leading to tumor angiogenesis. Oligonucleotides,14,100-113.
[95]Grossman, D. et al. (2001) Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc. Natl. Acad. Sci. U. S. A.98,635-640
[96]Mesri, M. et al. (2001) Cancer gene therapy using a survivin mutant adenovirus. J. Clin. Invest.108,981-990
[97]Senderowicz, A.M. et al. (1998) Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol.16, 2986-2999
[98]O'Connor, D.S. et al. (2000) Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am. J. Pathol.156,393-398
[99]Tran, J. et al. (1999) Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem. Biophys. Res. Commun.264, 781-788
[100]Mesri, M. et al. (2001) Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am. J. Pathol.158,1757-1765
[101]Grossman,D. et al. (1999) Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J. Invest. Dermatol.,113,1076-1081.
[102]Tu,S.P. et al. (2005) Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant. Gastroenterology,128,361-375.
[103]Grossman,D. et al. (2001) Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc. Natl Acad. Sci. USA,98,635-640.
[104]Mesri,M. et al. (2001) Cancer gene therapy using a survivin mutant adneovirus.J. Clin. Invest.,108,981-990.
[105]Yan,H. et al. (2006) Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable survivin antagonist. Oncogene,25,6968-6974.
[106]Lo,H.W. et al. (2005) Cancer-specific gene therapy. Adv. Genet.,54,235-255.
[107]Chen,J.S. et al. (2004) Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther.,11,740-747.
[108]Van Houdt,W.J. et al. (2006) The human survivin promoter:a novel transcriptional targeting strategy for treatment of glioma. J. Neurosurg.,104,583-592.
[109]Andersen,M.H. et al. (2002) Survivin—a universal tumor antigen. Histol. Histopathol.,17, 669-675
[110]Rohayem,J. et al. (2000) Antibody response to the tumor-associated inhibitor of apoptosis protein in cancer patients. Cancer Res.,60,1815-1817.
[111]Schmidt,S.M. et al. (2003) Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood,102, 571-576.
[112]Schmitz,M. et al. (2000) Generation of survivin-specific CD8t T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res.,60,4845-4849.
[113]Reker,S. et al. (2004) Identification of novel survivin-derived CTL epitopes.Cancer Biol. Ther.,3,173-179.
[114]Xiang,R. et al. (2005) A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res.,65,553-561.
[115]Otto,K. et al. (2005) Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine,23,884-889.
[116]Tsuruma,T. et al. (2004) Phase I clinical study of antiapoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J. Transl. Med.,2,19.
[2]AmbrosiniG,Adida C,Altieri DC:A novel anti-apoptosis gene,survivin,expressed in cancer and lymphoma.Nat Med 3:917-921,1997.
[3]Adida C,Crotty PL,McGrath J,Berrebi D,Diebold J,Altieri DC:Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation.Am J Pathol 152:43-49,1998.
[4]Grabowski P,Kuhnel T,Muhr-Wilkenshoff F,Heine B,Stein H,Hopfner M,Germer CT, Scherubl H:Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma.Br J Cancer 88:115-119,2003.
[5]Kato J,Kuwabara Y,Mitani M,Shinoda N,Sato A,Toyama T,Mitsui A,Nishiwaki T, Moriyama S,Kudo J et al:Expression of survivin in esophageal cancer:correlation with the prognosis and response to chemotherapy.Int J Cancer 95:92-95,2001.
[6]Ikeguchi M,Yamaguchi K,Kaibara N:Survivin gene expression positively correlates with proliferative activity of cancer cells in esophageal cancer.Tumour Biol 24:40-45,2003.
[7]Choi N,Baumann M,Flentjie M,Kellokumpu-Lehtinen P,Senan S,Zamboglou N, Kosmidis P:Predictive factors in radiotherapy for non-small cell lung cancer:present status.Lung Cancer 31:43-56,2001.
[8]Gianani R,Jarboe E,Orlicky D,Frost M,Bobak J,Lehner R,Shroyer KR:Expression of survivin in normal,hyperplastic,and neoplastic colonic mucosa.Hum Pathol 32:119-125,2001.
[9]Nassar A,Lawson D,Cotsonis G,Cohen C:Survivin and Caspase-3 Expression in Breast Cancer:Correlation With Prognostic Parameters,Proliferation,Angiogenesis, and Outcome.Appl Immunohistochem Mol Morphol,2008.
[10]潘艳东,黎静,李志强等.Ki67,VEGF和EGFR的表达与鼻咽癌临床分期及分化程度的关系[J]广东医学,2009;30(7)：1095-1097
[11]杨映红,林明稀,郑宇辉等.分化抑制蛋白IdⅠ和PCNA及Ki67在肝细胞癌中的表达及意义[J]中国肿瘤临床与康复,2008；15(1)：30-32
[12]蒋立艳,王自能.恶性上皮源性卵巢肿瘤多向分化与Ki67蛋白表达的相关性[J]暨南大学学报·自然科学与医学版,2006；(2)：257-261
[13]汲振余,赵立群,杨观瑞等.食管鳞癌细胞分化状态对内源性光敏剂PpIX产量的影响及对PDT的应答[J].世界华人消化杂志,2006,14(01)：6-11
[14]Zangemeister-WittkeU,SimonHU.An IAP in action the multiple roles of survivin in differentiation,immunity and malignance [J].Cell Cycle,2004,3(9):1121-1123
[15]Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003;22:8581-8589.
[16]Schmit t CA. Senescence,apoptosis and therapy—cutting the lifelines of cancer [J]. Nat Rev Cancer,2003,3 (4):2862295
[17]Shibata H,Mat subara O. Apoptosis as an independent prog2 nostic indicator in squamous cell carcinoma of the esophagus [J]. Pathol Int,2001,51 (7):498-503
[18]Altieri DC. Survivin,versatile modulation of cell division and apoptosis in cancer [J] Oncogene,2003,22 (53):8581-8589
[19]Ikeguchi M,Yamaguchi K,Kaibara N. Survivin gene expres2 sion positively correlates with proliferative activity of cancer cells in esophageal cancer [J]. Tumour Biol,2003,24 (1):402-405
[20]Grabowski P, Kii hnel T,Mii hr2Wilkenshoff F, et al. Prog2 nostic value of nuclear survivin expression in oesophageal squamous cell carcinoma[J]. Br J Cancer,2003,88 (1):115-119
[21]Nemoto T, Kitagawa M, Hasegawa M,et al. Expression of IAP family proteins in esophageal cancer [J]. Exp Mol Pathol,2004,76 (3):253-259
[22]9.Vagnarelli,P. et al. (2004) Chromosomal passengers:the four-dimensional regulation of mitotic events. Chromosoma,113,211-222
[23]Li,F. et al. (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature, 396,580-584.
[24]Li,F. et al. (1999) The cancer antiapoptosis mouse survivin gene:characterization of locus and transcriptional requirements of basal and cell cycledependent expression. Cancer Res.,59, 3143-3151.
[25]Kim,P.J. et al. (2003) Survivin and molecular pathogenesis of colorectal cancer. Lancet,362, 205-209.
[26]Gritsko,T. et al. (2006) Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res. 12,11-19.
[27]Song,J. et al. (2005) Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion. Immunity,22,621-631.
[28]Mitsiades,C.S. et al. (2002) Activation of NF-kB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene,21,5673-5683.
[29]Vogelstein,B. et al. (2004) Cancer genes and the pathways they control. Nat. Med.,10, 789-799.
[30. Xia,F. et al. (2006) Mitosis-independent survivin gene expression in vivo and regulation by p53. Cancer Res.,66,3392-3395.
[31]Marusawa,H. et al. (2003) HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J.,22,2729-2740.
[32]Dohi,T. et al. (2004) An IAP-IAP complex inhibits apoptosis. J. Biol. Chem.,279,34087-34090.
[33]. Dohi,T. et al. (2004) Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J.Clin. Invest.,114,1117-1127.
[34]O, Connor DS, Schechner S,Adida C,etal.Control of apoptosis during angiogenesis by survivin expression in endothelial cells[J].AmJ Pathol,2000,156(2):393-398.
[35]J. Taran, Z. Master, J.I. Yu, J. Rak, D.J. Dumont, R.S. Kerbel, A role of survivin in chemoresistance of endothelial cells mediated by VEGF, Proc. Natl Acad. Sci. USA 99 (2002) 4345-4349.
[36]X. Ling, F. Li, Silencing of anti-apoptotic survivin gene by multiple approaches of RNA interference technology, Biotech-niques 36 (2004) 450-454.
[37]N.K. Sah, A. Munshi, T. Mukhopadhyay, R.E. Meyn, Down regulation of the survivin gene shares HDAC and PI3K pathways and enhances radiosensitization of the human epidermoid carcinoma A431 cells, (submitted for publication).
[38]K.S. Choi, T.H. Lee, M.H. Jung, Ribozyme mediated cleavage of the human survivin mRNA and inhibition of anti-apoptotic function of survivin in MCF-7 cells, Cancer Gene Ther. 10 (2003) 87-95.
[39]M. Pennati, M. Binda, G Colella, M. Folini, L. Citti, R. Villa, et al., Radiosensitization of melanoma cells by ribozyme mediated inhibition of survivin expression, J. Invest. Dermatol.120 (2003) 648-654.
[40]F. Li, H. Huang, L. Brattain, P. Apontes, J. Wu, L. Binderup, M.G. Brattain, Differential expression of survivin and apoptosis by vitamin D3in two isogenic MCF-7 breast cancer cell sublines. Oncogene24 (2005) 1385-1395.
[41]Endl E, Gerdes J. The Ki-67 protein:fascinating forms and an unknown function. Exp. Cell Res.2000; 257; 231-237.
[42]Schluter C, Duchrow M, Wohlenberg C et al. The cell proliferation-associated antigen of antibody Ki-67:a very large,ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J. Cell Biol.1993; 123; 513-522.
[43]Hofmann K, Bucher P. The FHA domain:a putative nuclear signalling domain found in protein kinases and transcription factors. Trends Biochem. Sci.1995; 20; 347-349.
[44]Verheijen R, Kuijpers HJ, Schlingemann RO et al. Ki-67 detects a nuclear matrix-associated proliferation-related antigen. I. Intracellular localization during interphase. J. Cell Sci.1989; 92; 123-130.
[45]19. Rose DS, Maddox PH, Brown DC. Which proliferation markers for routine immunohistology? A comparison of (?)ve antibodies. J. Clin. Pathol.1994; 47; 1010-1014.
[46]Brown DC, Gatter KC. Monoclonal antibody Ki-67:its use in histopathology. Histopathology 1990; 17; 489-503.
[1]Ambosini G, Adida C, Altieti DC, etal.A novel anti-apoptosis gene,survivin,expressed in canser and lymphoma[J]. Nat Med,1997,3(8):917-921.
[2]Chantalatl,Skoufiasda,Klemanjp,et al.Crystal structure of human survivin reveals a bowtie-shaped dimer with two unusual alpha-helical extensions [J]. MolCell,2000, 6(1):183-189.
[3]Ambrosini G,Adidac ALTieri DC.A novel anti-apoptosis gene,survivin,expressed in cancer and Lymphoma[J].NatMed,1997,3(8):917'921.
[4]Sirieix PS,O'Donovan M,Brown J,et al.Surface expression of minichromosome maintenance proteins provides a novel method for detecting patients at risk for developing adenocarcinoma in Barrett's esophagus.Clin Cancer Res,2003,Vol.9(7):2560-2566
[5]Ambrosini QAdida C,Atieri DC.A novel anti-apoptosis gene,Survivin,expressed in cancer and lymphoma.Nat Med,1997,Vol.3(8):917-921
[6]Holley CL, Olson MR, Colon-Ramos DA, Kornbluth S:Reaper eliminates IAP proteins through stimulated IAP degradation and generalized translational inhibition. Nat Cell Biol 2002,4:439-444.
[7]Salvesen GS, Duckett CS:Apoptosis:IAP proteins:blocking the road to death's door. Nat Rev Mol Cell Biol 2002,3:401-410.
[8]Fraser AG, James C, Evan GI, Hengartner MO:Caenorhabditis elegans inhibitor of apoptosis protein (IAP) homologue BIR-1 plays a conserved role in cytokinesis. Curr Biol 1999, 9:292-301.
[9]Verdecia MA, Huang H, Dutil E, Kaiser DA, Hunter T, Noel JP:Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol 2000, 7:602-608.
[10]Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, Chung CW, Jung YK, Oh BH:An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and-7. Biochemistry 2001,40:1117-1123.
[11]Altieri DC:Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003,3:46-54.
[12]Zangemeister-Wittke U, Simon HU:An IAP in action:themultiple roles of survivin in differentiation, immunity and malignancy. Cell Cycle 2004,3:1121-1123.
[13]Wheatley SP, McNeish IA:Survivin:a protein with dual roles in mitosis and apoptosis. Int Rev Cytol 2005,247:35-88.
[14]Grossman D, Kim PJ, Blanc-Brude OP, Brash DE, Tognin S, Marchisio PC, Altieri DC: Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J Clin Invest 2001,108:991-999.
[15]Dohi T, Salz W, Costa M, Ariyan C, Basadonna GP, Altieri DC:Inhibition of apoptosis by survivin improves transplantation of pancreatic islets for treatment of diabetes in mice. EMBO Rep 2006,7:438-443.
[16]Okada H, Bakal C, Shahinian A, Elia A, Wakeham A, Suh WK,Duncan GS, Ciofani M, Rottapel R, Zuniga-Pflucker JC et al.:Survivin loss in thymocytes triggers p53-mediated growth arrest and p53-independent cell death. J Exp Med 2004,199:399-410.
[17]Jones G, Jones D, Zhou L, Steller H, Chu Y:Deterin, a new inhibitor of apoptosis from Drosophila melanogaster. J Biol Chem 2000,275:22157-22165.
[18]Walter D, Wissing S, Madeo F, Fahrenkrog B:The inhibitor-of-apoptosis protein Birlp protects against apoptosis in S. cerevisiae and is a substrate for the yeast homologue of Omi/HtrA2. J Cell Sci 2006,119:1843-1851.
[19]Huang HK, Bailis JM, Leverson JD, Gomez EB, Forsburg SL,Hunter T:Suppressors of Birlp (survivin) identify roles for the chromosomal passenger protein Piclp (INCENP) and the replication initiation factor Psf2p in chromosome segregation. Mol Cell Biol 2005, 25:9000-9015.
[20]Salvesen GS, Duckett CS:Apoptosis:IAP proteins:blocking the road to death's door. Nat Rev Mol Cell Biol 2002,3:401-410.
[21]Eckelman BP, Salvesen GS:The human anti-apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspases. J Biol Chem 2006,281:3254-3260.
[22]Vucic D, Franklin MC,Wallweber HJ, Das K, Eckelman BP, Shin H, Elliott LO, Kadkhodayan S, Deshayes K, Salvesen GS et al.:Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor:implications for Smac-dependent anti-apoptotic activity of ML-IAP. Biochem J 2005,385:11-20.
[23]Shin H, Renatus M, Eckelman BP, Nunes VA, Sampaio CA,Salvesen GS:The BIR domain of IAP-like protein 2 is conformationally unstable:implications for caspase inhibition. Biochem J 2005,385:1-10.
[24]Davoodi J, Lin L, Kelly J, Liston P, MacKenzie AE:Neuronal apoptosis-inhibitory protein does not interact with Smac and requires ATP to bind caspase-9. J Biol Chem 2004, 279:40622-40628.
[25]Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC:The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 1997,16:6914-6925.
[26]. Hao Y, Sekine K, Kawabata A, Nakamura H, Ishioka T, Ohata H, Katayama R, Hashimoto C, Zhang X, Noda T et al.:Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function. Nat Cell Biol 2004,6:849-860.
[27]Marusawa H, Matsuzawa S, Welsh K, Zou H, Armstrong R, Tamm I, Reed JC:HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J 2003,22:2729-2740.
[28]Dohi T, Okada K, Xia F, Wilford CE, Samuel T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S et al.:An IAP-IAP complex inhibits apoptosis. J Biol Chem 2004, 279:34087-34090.
[29]Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC:Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004,114:1117-1127.
[30]Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G:Cell death by mitotic catastrophe:a molecular definition. Oncogene 2004,23:2825-2837.
[31]Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003;22:8581-8589.
[32]. Grossman, D. et al. (1999) Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J. Invest. Dennatol.113,1076-1081
[33]Plantaz, D. et al. (1997) Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am. J. Pathol.150,81-89
[34]18 Islam, A. et al. (2000) High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19,617-623
[35]Hattori, M. et al. (2001) DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes. Cancer Lett.169,155-164
[36]Ambrosini,G. et al. (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med.,3,917-921.
[37]Fukuda,S. et al. (2006) Survivin, a cancer target with an emerging role in normal adult tissues. Mol. Cancer Ther.,5,1087-1098.
[38]. Mesri,M. et al. (2001) Suppression of vascular endothelial growth factormediated endothelial cell protection by survivin targeting. Am. J. Pathol.,158,1757-1765.
[39]Altznauer,F. et al. (2004) Inflammation-associated cell cycle-independent block of apoptosis by survivin in terminally differentiated neutrophils. J. Exp. Med.,199,1343-1354.
[40]Xing,Z. et al. (2004) Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J. Exp. Med.,199,69-80.
[41]Gurbuxani,S. et al. (2005) Differential requirements for survivin in hematopoietic cell development. Proc. Natl Acad. Sci. USA,102,11480-11485.
[42]Fukuda,S. et al. (2001) Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(t) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood,98,2091-2100. H.Deguchi,M. et al. (2002) Expression of survivin during liver regeneration. Biochem. Biophys. Res. Commun.,297,59-64.
[43]Chiou,S.K. et al. (2003) Survivin expression in the stomach:implications for mucosal integrity and protection. Biochem. Biophys. Res. Commun.,305,374-379.
[44]Wang,Y. et al. (2004) Survivin expression in rat testis is up-regulated by stem-cell factor. Mol. Cell Endocrinol.,218,165-174.
[45]Altieri,D.C. (2003) Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene,22,8581-8589.
[46]Florrel,S.R. et al. (2005) Proliferation, apoptosis, and survivin expression in a spectrum of melanocytic nevi. J. Cutan. Pathol.,32,45-49.
[47]Vetter,C.S. et al. (2005) Cytoplasmic and nuclear expression of survivin in melanocytic skin lesions. Arch. Dermatol. Res.,297,26-30.
[48]Velculescu,V.E. et al. (1999) Analysis of human transcriptomes. Nat. Gen.,23,387-388.
[49]Gritsko,T. et al. (2006) Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res.,12,11-19.
[50]Jiang,Y. et al. (2004) Aberrant regulation of survivin by the RB/E2F family of proteins. J. Biol. Chem.,279,40511-40520.
[51]Sommer,K.W. et al. (2003) Inhibitor of apoptosis protein (IAP) survivin is up-regulated by oncogenic c-H-Ras. Oncogene,22,4266-4280.
[52]Fukuda,S. et al. (2004) Activated H-Ras regulates hematopoietic cell survival by modulating survivin. Biochem. Biophys. Res. Commun.,323,636-644.
[53]Hoffman,W.H. et al. (2002) Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem.,277,3247-3257.
[54]Zhang,T. et al. (2001) Evidence that APC regulates survivin expression:a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res.,61,8664-8667.
[55]Fengzhi,L. et al. (2005) Nuclear or cytoplasmic expression of survivin:what is the significance? Int. J. Cancer,114,509-512.
[56]Islam,A. et al. (2000) Role of survivin, whose gene is mapped to 17q25, in human neuroblastoma and identification of a novel dominant-negative isoform, survivin-b/2B. Med. Pediatr. Oncol.,35,550-553.
[57]Monzo, M. et al. (1999) A novel anti-apoptosis gene:Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J. Clin. Oncol.17,2100-2104
[58]Tanaka, K. et al. (2000) Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin. Cancer Res.6,127-134
[59]Kawasaki, H. et al. (1998) Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res.58,5071-5074
[60]Kato, J. et al. (2001) Expression of survivin in esophageal cancer:Correlation with the prognosis and response to chemotherapy. Int. J. Cancer 95,92-95
[61]Yoshida, H. et al. (2001) Survivin, Bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell-and serous-type ovarian carcinomas. Int. J. Oncol.19,537-542
[62]Adida, C. et al. (2000) Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 96,1921-1925
[63]Sarela, A.I. et al. (2001) Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. Ann. Surg. Oncol.8,305-310
[64]Islam, A. et al. (2000) High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19,617-623
[65]Adida, C. et al. (2000) Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br. J. Haematol. 111,196-203
[66]Adida, C. et al. (1998) Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 351,882-883
[67]Swana, H.S. et al. (1999) Tumor content'of the anti-apoptosis molecule survivin and recurrence of bladder cancer. New Engl. J. Med.341,452-453
[68]Satoh, K. et al. (2001) Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 92,271-278
[69]. Schmitz, M. et al. (2000) Generation of survivin-specific CD8+T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res.60,4845-4849
[70]Andersen, M.H. et al. (2001) Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res.61,869-872
[71]Smith, S.D. et al. (2001) Urine detection of survivin and diagnosis of bladder cancer. J. Am. Med. Assoc.285,324-328
[72]O'Connor, D.S. et al. (2000) Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc. Natl. Acad. Sci. U. S. A.97,13103-13107
[73]Grossman,D. et al. (1999) Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J. Invest. Dermatol.,113,1076-1081.
[74]Cao,C. et al. (2004) XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene,23,7047-7052.
[75]Sharma,H. et al. (2005) Antisense-mediated downregulation of antiapoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy. Cancer Biol. Ther.,4,720-727.
[76]Fuessel,S. et al. (2004) Systematic in vitro evaluation of survivin directed antisense oligodeoxynucleotides in bladder cancer cells. J. Urol.,171,2471-2476.
[77]Ansell,S.M. et al. (2004) Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia,18,616-623.
[79]Sah,N.K. et al. (2006) Effect of downregulation of survivin expression on radiosensitivity of human epidermoid carcinoma cells. Int. J. Radiat. Oncol. Biol. Phys.,66,852-859. M.Pennati et al.1138
[80]Kanwar,J.R. et al. (2001) Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J. Natl Cancer Inst.,93,1541-1552.
[81]Izquierdo,M. (2005) Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther.,12,217-227.
[82]Carvalho,A. et al. (2003) Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J. Cell Sci.,116,2987-2998.
[83]Yang,D. et al. (2004) Cell division and cell survival in the absence of surviving. Proc. Natl Acad. Sci. USA,101,15100-15105.
[84]Ai,Z. et al. (2006) Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer. Cancer,107,746-756.
[85]Paduano,F. et al. (2006) Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygelda-namycin in human prostate cancer cells. Mol. Cancer Ther.,5,179-186.
[86]Nakao,K. et al. (2006) Survivin downregulation by siRNA sensitizes human hepatoma cells to TRAIL-induced apoptosis. Oncol. Rep.,16,389-392.
[87]Lens,S.M. et al. (2003) Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J.,22,2934-2947.
[88]Beltrami,E. et al. (2004) Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis. J. Biol. Chem.,279, 2077-2084.
[89]Jiang,G. et al. (2006) Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma. Cancer Biol. Ther.,5,435-440.
[90]93. Jiang,G. et al. (2006) Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma. Cancer Biol. Ther.,5,435-440.
[91]Li,Q.X. et al. (2006) Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers. Cancer Biol. Ther.,5,860-866.
[92]Yonesaka,K. et al. (2006) Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin. Int. J. Cancer,118,812-820.
[93]Kappler,M. et al. (2005) Radiosensitization after a combined treatment of survivin siRNA and irradiation, is correlated with the activation of caspases 3 and 7 in a wt-p53 sarcoma cell line, but not in a mt-p53 sarcoma cell line. Oncol. Rep.,13,167-172.
[94]Coma,S. et al. (2004) Use of siRNAs and antisense oligonucleotides against survivin RNA to inhibit steps leading to tumor angiogenesis. Oligonucleotides,14,100-113.
[95]Grossman, D. et al. (2001) Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc. Natl. Acad. Sci. U. S. A.98,635-640
[96]Mesri, M. et al. (2001) Cancer gene therapy using a survivin mutant adenovirus. J. Clin. Invest.108,981-990
[97]Senderowicz, A.M. et al. (1998) Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol.16, 2986-2999
[98]O'Connor, D.S. et al. (2000) Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am. J. Pathol.156,393-398
[99]Tran, J. et al. (1999) Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem. Biophys. Res. Commun.264, 781-788
[100]Mesri, M. et al. (2001) Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am. J. Pathol.158,1757-1765
[101]Grossman,D. et al. (1999) Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J. Invest. Dermatol.,113,1076-1081.
[102]Tu,S.P. et al. (2005) Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant. Gastroenterology,128,361-375.
[103]Grossman,D. et al. (2001) Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc. Natl Acad. Sci. USA,98,635-640.
[104]Mesri,M. et al. (2001) Cancer gene therapy using a survivin mutant adneovirus.J. Clin. Invest.,108,981-990.
[105]Yan,H. et al. (2006) Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable survivin antagonist. Oncogene,25,6968-6974.
[106]Lo,H.W. et al. (2005) Cancer-specific gene therapy. Adv. Genet.,54,235-255.
[107]Chen,J.S. et al. (2004) Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther.,11,740-747.
[108]Van Houdt,W.J. et al. (2006) The human survivin promoter:a novel transcriptional targeting strategy for treatment of glioma. J. Neurosurg.,104,583-592.
[109]Andersen,M.H. et al. (2002) Survivin—a universal tumor antigen. Histol. Histopathol.,17, 669-675
[110]Rohayem,J. et al. (2000) Antibody response to the tumor-associated inhibitor of apoptosis protein in cancer patients. Cancer Res.,60,1815-1817.
[111]Schmidt,S.M. et al. (2003) Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood,102, 571-576.
[112]Schmitz,M. et al. (2000) Generation of survivin-specific CD8t T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res.,60,4845-4849.
[113]Reker,S. et al. (2004) Identification of novel survivin-derived CTL epitopes.Cancer Biol. Ther.,3,173-179.
[114]Xiang,R. et al. (2005) A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res.,65,553-561.
[115]Otto,K. et al. (2005) Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine,23,884-889.
[116]Tsuruma,T. et al. (2004) Phase I clinical study of antiapoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J. Transl. Med.,2,19.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |